Single-dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration.
Fluphenazine decanoate is commonly used as part of maintenance treatment of schizophrenia, but its pharmacokinetics are poorly understood. We administered a single intramuscular dose of fluphenazine decanoate to nine patients and found that plasma fluphenazine level did not decline to 50% of the peak level by day 26 in any of the patients. This means that it has a long half-life measurable in months rather than weeks.
Simpson
G M
GM
Department of Psychiatry, Medical College of Pennsylvania, Eastern Pennsylvania Psychiatric Institute, Philadelphia 19129.
Yadalam
K G
KG
Levinson
D F
DF
Stephanos
M J
MJ
Lo
E S
ES
Cooper
T B
TB
D000328:Adult; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D005476:Fluphenazine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D006220:Haloperidol / Q000008:administration & dosage / Q000493:pharmacokinetics; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008657:Metabolic Clearance Rate / Q000502:physiology; D011618:Psychotic Disorders / Q000097:blood* / Q000188:drug therapy
C011825:fluphenazine depot; D006220:Haloperidol; D005476:Fluphenazine